Johnson & Johnson (JNJ)vsWORK Medical Technology Group LTD Ordinary Shares (WOK)
JNJ
Johnson & Johnson
$265.58
-0.29%
HEALTHCARE · Cap: $640.02B
WOK
WORK Medical Technology Group LTD Ordinary Shares
$1.88
-2.59%
HEALTHCARE · Cap: $9.38M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 913596% more annual revenue ($97.93B vs $10.72M). JNJ leads profitability with a 21.5% profit margin vs -41.9%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
WOK
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.9%
Fair Value
$140.57
Current Price
$265.58
$125.01 premium
Intrinsic value data unavailable for WOK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
19.1% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 0.9%
Grey zone — moderate risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -5.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : WOK
The strongest argument for WOK centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 19.1% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : WOK
The primary concerns for WOK are Altman Z-Score, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
JNJ profiles as a mature stock while WOK is a growth play — different risk/reward profiles.
WOK carries more volatility with a beta of 1.75 — expect wider price swings.
WOK is growing revenue faster at 19.1% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 35/100), backed by strong 21.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →WORK Medical Technology Group LTD Ordinary Shares
HEALTHCARE · MEDICAL DEVICES · USA
WORK Medical Technology Group Ltd is a pioneering player in the medical technology sector, dedicated to the advancement of healthcare through the research, development, and commercialization of innovative medical devices. The company's diverse portfolio is designed to tackle pressing challenges in global healthcare, underscoring its commitment to improving patient outcomes. With a strong emphasis on quality, innovation, and responsiveness to market demands, WORK is ideally positioned for sustainable growth, making it an attractive investment opportunity for institutional investors seeking exposure to transformational healthcare solutions in an evolving industry landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?